-

Respira Technologies, Inc. Rebrands as “QNOVIA”; Adopts Qnovia, Inc. as Corporate Name

LOS ANGELES--(BUSINESS WIRE)--Respira Technologies, Inc.—a clinical-stage company developing inhaled therapeutics for smoking cessation and drug delivery technologies to treat cardiopulmonary diseases—has rebranded as “QNOVIA” and adopted Qnovia, Inc. as its corporate name. As part of the rebranding, the company has migrated to a new website (https://www.qnovia.com).

The company is advancing to an IND submission and is securing financing for human clinical trials. As the company advances, this rebranding will further differentiate the company’s technology and products from others in the biotechnology space.

This news follows the recent appointment of Brian Quigley as CEO of the company. Previously, Quigley served as COO. Quigley is a former executive at Altria Group, Inc., where he worked for 16 years. For seven of those years, Quigley served as President & CEO of Altria’s Smokeless and Innovative Products/Vapor Businesses. Quigley has over 15 years of business leadership experience in driving innovation and shareholder returns in regulated industries.

About Qnovia, Inc. (formerly Respira Technologies, Inc.)

Qnovia, Inc. is a health tech company focused on commercializing proprietary inhalation device technologies to improve patient outcomes. The company is currently engaged with FDA CDER to pursue a combination product authorization as the first inhalable prescription smoking cessation therapy.

The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies.

The company’s key product, the RespiRx™ device, is the first orientation-agnostic, portable VMN device that effectively operates in any position held by the patient. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of Asthma, COPD, Vaccine Delivery, Pain Management, and several generic as well as select investigational new drugs with safe and effective inhalable drug delivery mechanisms that only the RespiRx™ device can deliver.

Qnovia, Inc. is backed by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, Poseidon Asset Management and TL Capital Group LLC.

Contacts

Investor Relations Contact:
Qnovia, Inc.
IR@qnovia.com

Media Relations Contact:
Richard Laermer
RLM PR
212-741-5106 X 216
Qnovia@RLMpr.com

Industry:

Qnovia, Inc.

Release Versions
English

Contacts

Investor Relations Contact:
Qnovia, Inc.
IR@qnovia.com

Media Relations Contact:
Richard Laermer
RLM PR
212-741-5106 X 216
Qnovia@RLMpr.com

More News From Qnovia, Inc.

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced the appointment of four new members to its Scientific Advisory Board (SAB). The new members include Neal Benowitz, MD, Professor at University of California at San Francisco, Ian M. Fearon, PhD, independent consultant, Darla E. Kendzor, PhD, Professor at University of...

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced positive results from its first in-human study of QN-01, the company’s lead asset. QN-01 is an inhaled smoking cessation therapy that is currently being evaluated in the U.S. under FDA’s Center for Drug Evaluation and Research (CDER) and in the U.K. by the Medicines and Health...

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

RICHMOND, Va.--(BUSINESS WIRE)--Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs. Qnovia will work with UVA School of Medicine investigators Dr. Molly Hughes and Dr. Matthew Crawford to combine Qnovia’s RespiRxTM inhaled drug delivery platform and UVA’...
Back to Newsroom